Holen Sie sich die Stockscreener-App
4.72
6.79%
0.30
Handel nachbörslich:
4.72
Schlusskurs vom Vortag:
$4.42
Offen:
$4.39
24-Stunden-Volumen:
89,460
Relative Volume:
1.52
Marktkapitalisierung:
$90.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-34.17M
KGV:
-2.0853
EPS:
-2.2635
Netto-Cashflow:
$-47.63M
1W Leistung:
+11.58%
1M Leistung:
+12.65%
6M Leistung:
+41.11%
1J Leistung:
+74.88%
1-Tages-Spanne:
$4.39
$4.72
1-Wochen-Bereich:
$4.20
$4.72
52-Wochen-Spanne:
$2.44
$5.12
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.72 | 84.35M | 0 | -34.17M | -47.63M | -2.2635 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Eingeleitet | Roth Capital | Buy |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-09-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-07-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-07-21 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-07-21 | Eingeleitet | Barclays | Overweight |
| 2020-07-21 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Polypid Ltd Aktie (PYPD) Neueste Nachrichten
PolyPid To Present Phase 3 SHIELD II Data Showing Sustained Local Doxycycline Release And Minimal Systemic Exposure At ESCMID 2026 Conference - Sahm
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026 - markets.businessinsider.com
PolyPid to present D-PLEX100 pharmacokinetic data at ESCMID Global By Investing.com - Investing.com India
In a Phase 3 surgery trial, PolyPid's antibiotic released for 32 days - Stock Titan
Short Covering: How much upside does PolyPid Ltd have2026 Key Lessons & Weekly High Return Stock Forecasts - baoquankhu1.vn
PolyPid Ltd. (NASDAQ:PYPD) Sees Significant Growth in Short Interest - MarketBeat
PYPD Options Volatility — NASDAQ:PYPD - TradingView — Track All Markets
PYPD Options Chain — NASDAQ:PYPD - TradingView — Track All Markets
Market Rankings: Is PolyPid Ltd likely to announce a buybackPortfolio Gains Summary & Smart Swing Trading Techniques - baoquankhu1.vn
PYPD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Gainers: Does PolyPid Ltd have high return on assets2026 Technicals & Target Return Focused Stock Picks - baoquankhu1.vn
PolyPid Ltd. (NASDAQ:PYPD) Q4 2025 earnings call transcript - MSN
PolyPid (PYPD) director submits initial Form 3 ownership - Stock Titan
PolyPid (PYPD) director details vested and future stock options - Stock Titan
Total equity of PolyPid Ltd. – FWB:2PV - TradingView
Total debt of PolyPid Ltd. – FWB:2PV - TradingView
PolyPid Ltd. Balance Sheet – FWB:2PV - TradingView
Cash per share of PolyPid Ltd. – FWB:2PV - TradingView — Track All Markets
PolyPid Ltd. Stock (2PV)Quote Deutsche Boerse AG - marketscreener.com
PolyPid Ltd.: Target Price Consensus and Analysts Recommendations | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Revenue and Earnings Analysts Forecasts Revisions | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Financial Data Forecasts Estimates and Expectations | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Shareholders Board Members Managers and Company Profile | IL0011326795 - marketscreener.com
PolyPid Ltd.: Fundamental Analysis and Financial Ratings | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Performance & Quotes, 2PV Stock Price on Deutsche Boerse AG Exchange - marketscreener.com
Taxes of PolyPid Ltd. – FWB:2PV - TradingView
2PV: Static price chart | PolyPid Ltd. | IL0011326795 - marketscreener.com
Net income of PolyPid Ltd. – FWB:2PV - TradingView
2PV Stock Price and Chart — FWB:2PV - TradingView
PolyPid begins rolling NDA submission for surgical infection drug By Investing.com - Investing.com South Africa
PYPD Should I Buy - Intellectia AI
Polypid Ltd Initiates D-Plex100 Nda Submission to Fda - MarketScreener
PolyPid’s Moment Is Here: NDA Submission Begins as a High-Impact Catalyst Stack Takes Shape (NASDAQ: PYPD) - TipRanks
Risk Check: Does PolyPid Ltd stock benefit from AI growth2026 Performance Recap & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Polypid initiates D-Plex100 NDA submission to the FDA - marketscreener.com
PolyPid begins rolling NDA submission for surgical infection drug - Investing.com
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA - Bitget
PolyPid (PYPD) advances Fast Track NDA for D-PLEX100 after strong Phase 3 data - Stock Titan
Aug Closing: How does PolyPid Ltd score in quality rankingsFed Meeting & Low Risk Entry Point Tips - baoquankhu1.vn
Insider Buy: Does PolyPid Ltd have high return on assetsBear Alert & Short-Term Swing Trade Alerts - baoquankhu1.vn
Patterns Watch: How much upside does PolyPid Ltd haveMarket Volume Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
PolyPid Ltd Stock: Innovative Drug Delivery Solutions in a Competitive Biotech Landscape - AD HOC NEWS
PolyPid (PYPD) COO details stock option and share holdings - Stock Titan
PolyPid (PYPD) director Dror-Darwish Nir lists six vested option grants - Stock Titan
PolyPid (PYPD) CFO details extensive employee stock option awards - Stock Titan
PolyPid (PYPD) director Barenholz discloses shares and multiple option grants - Stock Titan
PolyPid (PYPD) director Joseph BenAmram reports initial stock option grants - Stock Titan
PolyPid | 3: Initial statement of beneficial ownership of securities- BenAmram Joseph - Moomoo
Pullback Watch: Whats the beta of PolyPid Ltd stock2026 Risk Factors & Verified Short-Term Trading Plans - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: PolyPid (PYPD), Axsome Therapeutics (AXSM) - The Globe and Mail
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Finanzdaten der Polypid Ltd-Aktie (PYPD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):